G20 Health Ministers Receive Flurry Of Requests Ahead Of Their First-Ever Meeting 18/05/2017 by Monika Ermert for Intellectual Property Watch Leave a Comment Civil society organisations and the Business 20 Dialogue all put their positions on the table before the opening of the first-ever meeting of G20 Health Ministers tomorrow in Berlin, Germany taking place tomorrow.
March-in Rights: A Lost Opportunity To Lower US Drug Prices 18/05/2017 by Steven Seidenberg for Intellectual Property Watch 17 Comments It appears not just unfair, but absurdly so. The US government paid for research that produced a patented drug, the patents were licensed exclusively to a Japanese firm, and that firm is now committing price discrimination against the US. Astellas Pharma is selling its anti-prostate cancer drug, Xtandi, for over $129,000 per year per patient in the United States – triple the price of the drug in Japan. Alas, this situation is not unusual. Many drugs that were financed by US taxpayers are sold in the US at exorbitant prices, but are much cheaper in other high-income industrialized nations. This differential price problem could be solved easily. However, the US government has consistently refused to exercise its march-in rights in order to lower drug prices.
Major Research Funders, Institutions Pledge Transparency In Clinical Trials 18/05/2017 by Intellectual Property Watch Leave a Comment More transparency on clinical trials is expected after major research funders, research institutions, and international health groups agreed that the research they fund or support will publicly release results of clinical trials.
New Industry Alliance Aimed At Antimicrobial Resistance 18/05/2017 by Intellectual Property Watch Leave a Comment Pharmaceutical industry representatives today announced a new alliance to fight antimicrobial resistance. The announcement came during a meeting of the private sector of the most advanced countries.
Attacks On WHO Candidate Are Defamatory, ‘Colonial’, Ambassador Says 17/05/2017 by Catherine Saez, Intellectual Property Watch 1 Comment The African Union delegation to the United Nations came in outspoken numbers to a press briefing today to express unshakable support for the Ethiopian candidate to be the next head of the World Health Organization, Tedros Adhanom Ghebreyesus.
IFPMA Priorities At WHA: Election, Antibiotics, Cancer, Pandemics 17/05/2017 by Catherine Saez, Intellectual Property Watch Leave a Comment The new head of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has hit the ground running in Geneva, and is weighing in on a variety of policy issues, this week providing a list of priorities for the research-based pharma industry at the upcoming annual World Health Assembly.
World Health Assembly Topic: Pandemic Flu Financing, Virus Sharing, Extension 17/05/2017 by Catherine Saez, Intellectual Property Watch Leave a Comment There are many who see the World Health Organization mechanism to prepare and face the next influenza pandemic and insure availability of treatments as a success. However, some questions remain.
IP-Watch Guide To 2017 World Health Assembly: Election, Budget, Antibiotics, Cancer, R&D And More 16/05/2017 by Catherine Saez, Intellectual Property Watch 1 Comment In a few days, the 70th World Health Assembly will open its doors in Geneva with a marathon agenda, and over 4,000 registered delegates. The election of a new director general, the approval of the budget for the next biennium (2018/2019) are set to capture the attention of member states. However, many other subjects require their consideration, such as a resolution on cancer treatment costs, research and development for epidemic diseases, for new antibiotics, for medicines affecting primarily poor populations, access to medicines, and the influenza pandemic preparedness framework.
Longest, Biggest World Health Assembly Ever Set To Open With Election, Budget Topping Agenda 12/05/2017 by Catherine Saez, Intellectual Property Watch 4 Comments The 70th World Health Assembly opening in a few days is the WHA of superlatives, according to a World Health Organization’s official. It is the longest assembly ever, with nine days of meeting, the largest number delegates, of agenda items, and of documents. It is also when the new WHO new director general will be elected, and when the WHO next budget is expected to be approved.
WHO, Stakeholders Take ‘First Step’ On Fair Pricing For Medicines 12/05/2017 by Catherine Saez and William New, Intellectual Property Watch 3 Comments The World Health Organization has concluded a major one-day forum on fair pricing of medicines, bringing a wide range of stakeholders together in Amsterdam and coming up with several possible actions for the way ahead. Key points of discussion included a definition of fair pricing, moving away from value-based pricing, delinkage of price from research and development costs, and greater transparency, according to participants.